Enveric Biosciences, INC 10-Q quarterly reports

Enveric Biosciences reports Q1 2026 results, highlighting progress on lead candidate EB-003 and a recent capital raise, while addressing ongoing liquidity concerns.

Enveric Biosciences reports continued losses and substantial doubt about its ability to continue as a going concern, despite recent capital raises and Nasdaq compliance.

Enveric Biosciences reported an increased net loss for the second quarter and first half of 2025, driven by higher research and development expenses, while raising capital through equity offerings.

Enveric Biosciences reports a net loss of $2.18 million for the first quarter of 2025, alongside updates on its drug development programs and recent financing activities.

Enveric Biosciences reports a net loss of $2.08 million for the third quarter of 2024, alongside ongoing efforts to secure additional funding and maintain Nasdaq listing compliance.

Enveric Biosciences reported its second quarter 2024 results, highlighting ongoing losses and substantial doubt about its ability to continue as a going concern, while also detailing progress in its clinical programs and financial activities.

Enveric Biosciences reports a net loss of $2.46 million for the first quarter of 2024, while highlighting advancements in its neuroplastogenic small-molecule therapeutics pipeline and securing additional funding.